JCI: Old medicine new results! Scientists have found four drugs that may be effective in treating HIV infection!

, July 3, 2020 /PRNewswire/
-- In a recent study published in the international journalJournal of Clinical Investigation
, scientists from yale institutions such as Yale University identified four drugs that could help reduce the long-term health effects of HIV infectionPicture Source: NIAID
Practice has proved that antiretroviral therapy is an effective therapeutic means to save the lives of HIV-infected people, but even after treatment, most patients in the body of certain immune cells still lurking HIV virus, the presence of inactive HIV in the genome or will induce the body's chronic immune system activation, thus accelerating the body aging, and promote patients to cardiovascular disease and some cancers become abnormally susceptible'It's likediabetes, patients can get good treatments, but they also experience serious health consequences, and antiretroviral therapy alone may not be enough to suppress the body's chronic immune system activation, so we need to develop new drugs,' said Professor Ya-Chi Ho, aresearcherHiv reactivated and reduced the responsiveness of the immune system, screening 1,430 drugs approved by theFDAto assess the effects of HIV on infected human cells, and finally the researchers targeted four approved drugs that inhibited potential HIV activation while also reducing the damaging immune system responsetwo of these drugs are now used to treat HIV infectionclinical trials, the drug ruxolitinib, which is used to treat blood disorders, and mycophenolic acid, which inhibits organ rejection, however, the researchers found that the other two drugs, filgotinib and Spironolactone can also inhibit hiv reactivation and HIV-induced immunactivation, and filgotinib regulates the immune response and is used to treat autoimmune diseases, while an abody schuthoson is a hormone drug that can be used to treat heart failure These HIV inhibitors may be used to supplement antiretroviral therapy during HIV treatment, thereby reducing chronic immunoactivation in the patient's body, and the use of antiretroviral therapy alone does not seem to achieve this goal; (BioValleyBioon.com) original origins: Yang-Hui Jimmy Yeh, Katharine M Jenike, Rachela M Calvi, et al.
Filgotinib suppresses HIV-1-driven gene rillion by inhibiting HIV-1 splicing and T cell activation , Journal of Clinical , June 23, 2020, doi: 10.1172/JCI137371